Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical BGNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 1.96% | |
| MACD Bearish Signal Line Cross | Bearish | 2.87% | |
| 20 DMA Support | Bullish | 2.87% | |
| Multiple of Ten Bullish | Other | 2.87% | |
| 180 Bullish Setup | Bullish Swing Setup | 1.00% | |
| Multiple of Ten Bullish | Other | 1.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.03% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Biopharmaceutical Cancers Monoclonal Antibodies Oncogenes Humanized Antibody Lymphomas Ras Subfamily Braf Kras
Biopharmaceutical Cancers Monoclonal Antibodies Oncogenes Humanized Antibody Lymphomas Ras Subfamily Braf Kras
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 210.35 |
| 52 Week Low | 113.01 |
| Average Volume | 315,662 |
| 200-Day Moving Average | 155.85 |
| 50-Day Moving Average | 150.22 |
| 20-Day Moving Average | 158.23 |
| 10-Day Moving Average | 164.36 |
| Average True Range | 6.80 |
| ADX | 20.83 |
| +DI | 24.91 |
| -DI | 17.61 |
| Chandelier Exit (Long, 3 ATRs ) | 151.00 |
| Chandelier Exit (Short, 3 ATRs ) | 156.88 |
| Upper Bollinger Band | 176.63 |
| Lower Bollinger Band | 139.83 |
| Percent B (%b) | 0.7 |
| BandWidth | 23.26 |
| MACD Line | 3.20 |
| MACD Signal Line | 3.36 |
| MACD Histogram | -0.1588 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 179.00 | ||||
| Resistance 3 (R3) | 178.18 | 172.88 | 176.75 | ||
| Resistance 2 (R2) | 172.88 | 169.45 | 173.29 | 176.00 | |
| Resistance 1 (R1) | 169.21 | 167.34 | 171.05 | 170.03 | 175.26 |
| Pivot Point | 163.91 | 163.91 | 164.83 | 164.32 | 163.91 |
| Support 1 (S1) | 160.24 | 160.48 | 162.08 | 161.06 | 155.82 |
| Support 2 (S2) | 154.94 | 158.37 | 155.35 | 155.08 | |
| Support 3 (S3) | 151.27 | 154.94 | 154.33 | ||
| Support 4 (S4) | 152.09 |
